Otsuka buys Astex for $807mm
Executive Summary
Japanese drug and nutraceuticals firm Otsuka Pharmaceutical Co. Ltd. has agreed to pay $8.50 per share (a 40% premium), or $807mm, to acquire Astex Pharmaceuticals Inc., a public US cancer drug development company. The value of the deal using the treasury stock method, which takes into account options and equivalents, is reported to be $886mm.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
- Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Cash
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice